The Technion’s story has been intertwined with Israel’s for more than a century, from laying the foundations for a new nation to shaping its future.
Step inside Israeli innovation at the David and Janet Polak Visitors Center. Experience our 360° immersive movie and tech exhibition. Open to individuals and groups.
Learn More
A group of researchers from the Technion – Israel Institute of Technology, and the United States has reported a breakthrough in MRI scanning that could significantly improve breast cancer diagnosis, according to a paper published in Nature Communications. The researchers developed a new method, called ELITE, that accelerates and enhances MRI scans used in breast cancer imaging, a disease diagnosed in approximately 2.3 million people each year, most of them women. The approach combines artificial intelligence with advanced mathematical modeling to enable dynamic MRI imaging at what the researchers describe as unprecedented speed and accuracy. The international study brings together…
As a Ph.D. student in the Wolfson Faculty of Chemical Engineering at the Technion, O.V. was busy developing a novel tool to target breast cancer tumors aiming to reduce the severe side effects of chemotherapy. Having tested positive for the breast cancer mutation gene herself, O. was motivated to focus her academic work on breast […]
Researchers at the Technion – Israel Institute of Technology have developed an artificial intelligence (AI) model designed to help guide whether to administer chemotherapy directly after tumor resection in breast cancer patients. The model, which uses high-resolution images from hematoxylin and eosin (H&E)-stained tumor samples collected at the time of diagnosis, predicts both the risk of cancer recurrence and the likelihood that a patient will benefit from chemotherapy. The research, published in The Lancet Oncology, identifies patterns and signals in the tumor that might otherwise escape detection. “These are complex biological signals that the human eye cannot consistently quantify,” said…
In my final year as a Technion undergraduate, I tested positive for a BRCA mutation. This means I face an increased risk for breast and other cancers. This revelation altered the course of my life — making my longstanding desire to do scientific research not just an academic pursuit, but a personal one. I earned […]
IceCure Medical’s tumor-freezing treatment ProSense has nabbed FDA approval, making it the first medical device of its kind to be endorsed for the local treatment of breast cancer. The Israeli medical technology company saw its shares jump more than 17% afterhours Friday, Oct. 3, after the company announced the approval. Shares lost some of their gains by Monday morning and were trading up about 8% from Friday’s close. Treatment with ProSense involves a minimally invasive outpatient procedure that aims to destroy tumors by freezing them, all without the need for surgical removal of breast tissue. This approach also allows for…
Maayan Kinsbursky “I am a 31-year-old industrial designer, a wife, and a mother to a baby. I hold a bachelor’s degree in industrial design from Bezalel Academy of Arts and Design and a master’s degree in industrial design from the Technion – Israel Institute of Technology, which I completed with honors. My thesis focused on […]
Hen Davidov and Noam Morris have been selected as the 2025 Rhodes Scholars from Israel, earning a prestigious opportunity to pursue advanced degrees at Oxford University this fall. The Rhodes Scholarship, the world’s oldest and most prestigious, provides a comprehensive scholarship package worth up to $320,000 per student, covering tuition, living expenses, and more. This year’s selection process was unprecedented. The Rhodes Foundation extended its application deadline by two weeks due to the war in Israel. Many potential candidates were called to active or reserve military duty, making the extension essential for ensuring participation. Davidov, 25, from Haifa, is a…
This 3D-printed postmastectomy bra could be the next best breast prosthesis. Here’s how the technology works. Tal was diagnosed with stage 3 breast cancer in the fall of 2019. She underwent chemotherapy, a mastectomy, and whole breast radiation. Tal wasn’t a candidate for reconstructive surgery, because radiation thinned her skin and reduced its elasticity. Determined to move on and regain confidence, she tried her first breast prosthesis at a hospital. “It was knitted and looked like a pillow,” she says. “It made me laugh because it looked nothing like a real breast.” U·Bra was co-developed by Technion Professor Yoav Sterman.
Researchers studying artificial intelligence training data, better predictions of extreme weather events and treatment of swelling linked to breast cancer are among the eight Cornell assistant professors who recently received National Science Foundation Faculty Early Career Development Awards. Each will receive a minimum of $400,000 over five years from the program, which supports early-career faculty “who have the potential to serve as academic role models in research and education and to lead advances in the mission of their department or organization,” according to the NSF. Each funded project must include an educational component.
An Israeli medtech company whose novel therapy freezes and destroys malignant tumors has announced positive results in a trial of breast cancer patients. IceCure Medical’s ProSense system uses extremely cold liquid (cryoablation) to freeze and destroy abnormal tumors as an alternative to surgical removal. Its focus is currently on early-stage breast, lung, liver and kidney tumors. While cryoablation is not a new process, IceCure Medical’s system allows physicians to perform the procedure in their own offices, with no need for hospitalization. The company’s ICE3 study is the largest multicenter clinical trial performing cryoablation on low-risk and early-stage breast cancer tumors….
Pictured Above / L-R: Amir Livne, Dr. Gil Shamai and Prof. Ron Kimmel One in nine women globally will be diagnosed with breast cancer during their lifetime, and the numbers are only increasing as a result of factors, including increased lifespan and modern lifestyles. Personalized immunotherapy treatment is a necessity now more than ever, but the number of doctors and pathologists who specialize in examining tissue for specific diagnoses needed for personalized medicine is declining. To help combat this problem, Technion researchers have developed an artificial intelligence (AI) neural network that simplifies and improves the diagnostic process. Even better, the…